Skip to search formSkip to main contentSkip to account menu

AZD3514

Known as: Androgen Receptor Downregulator AZD3514, SARD AZD3514 
An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514… 
National Institutes of Health

Related topics

Related topics

4 relations
AR protein, humanInhibition of Cell ProliferationTranslational Repression

Broader (1)

Pyridazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles
ObjectivesTo investigate the relationships between interferon alpha (IFNα) and the clinical and serological phenotype of patients… 
2018
2018
Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
The androgen receptor (AR) is expressed in 60%–70% of breast cancers regardless of estrogen receptor status, and has been… 
2016
2016
Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data
BackgroundThe continual reassessment method (CRM) requires an underlying model of the dose-toxicity relationship (“prior skeleton… 
2016
2016
Voie de signalisation des androgènes, altérations génomiques et progression du cancer de la prostate
La voie de signalisation du recepteur des androgenes (RA) reste une cible therapeutique privilegiee dans les cancers de la… 
Review
2015
Review
2015
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
2015
2015
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
SummaryBackground AZD3514 is a first-in-class, orally bio-available, androgen-dependent and -independent androgen receptor… 
Highly Cited
2013
Highly Cited
2013
AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after… 
2013
2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
2013
2013
A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).
4511 Background: AZD3514 is a first in class, orally bio-available drug that inhibits androgen-dependent and –independent… 
2012
2012
Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer
The androgen receptor (AR), an important molecular target in the aetiology and progression of prostate cancer, has been found… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)